PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Goddard et al. (as amended)
Appl. No.	:	10/063,549
Filed	:	May 2, 2002
For	:	POLYPEPTIDES ENCODED BY A NUCLEIC ACID OVEREXPRESSED IN ESOPHAGEAL AND KIDNEY TUMOR (as amended)
Examiner	:	Patricia Ann Duffy
Group Art Unit	:	1645

DECLARATION UNDER 37 CFR §1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We declare and state as follows:

1. We are the inventors of the invention claimed in the above-captioned patent application.

2. During the time period in which we participated in the events and activities described herein, we were employed by Genentech, Inc., the assignee of the above-captioned application.

3. All of the events and activities described herein were performed by us personally, or by others at our direction as part of our duties as employees of Genentech, Inc.

4. The subject matter and utility of the claimed invention in the above-captioned patent application was conceived prior to June 11, 1998 and diligently reduced to practice thereafter in the U.S. as described below.

5. Prior to June 11, 1998, I and/or my co-inventors conceived of the invention claimed in the above-captioned patent application. Prior to June 11, 1998, the idea of investigating several newly discovered DNA sequences for their relevance, including developing primers and cloning the DNA sequences of interest from normal and tumor tissues, was conceived. The sequences of SEQ ID NOs: 45 and 46 were first disclosed in U.S. Provisional Application 60/088863, filed June 11,1998, as SEQ ID NOs: 1 and 3, in Figures 1A-B and 2. Antibodies to said polypeptides sequence were also contemplated as disclosed in the provisional application. In addition, various utilities for the disclosed nucleic acids, polypeptides, and antibodies, including use as diagnostic

-1-

agents, were also conceived prior to June 11, 1998, and included in the provisional application. Thus, conception of the invention claimed in the above-captioned patent application occurred prior to June 11, 1998.

6.   After these initial experiments, we continued to produce primers, clone and sequence other DNA sequences. We then began to identify the expression levels of the cloned sequences, and created constructs for expression of the encoded proteins. PCR primers for use in the detection of DNA58850 expression were designed on March 6, 2000 (see Exhibit A).

7.   Thereafter, the primers were used to test for expression of DNA58850 in various normal and tumor tissues. Exhibit B shows an experiment conducted in March 2000 testing for expression of DNA58850 in various normal tissues. Exhibit C shows an experiment performed on June 13, 2000, in which the primers were used to determine the expression level of DNA58850 in various tumor samples and their normal tissue counterparts. These gel data demonstrate that DNA58850 is more highly expressed in esophageal and kidney tumor than in normal esophageal and kidney tissue, respectively. These exhibits show diligence in reducing to practice following conception of the invention. Thus, we conceived of the present invention prior to June 11, 1998 and were diligent in reducing the invention to practice by at least June 13, 2000.

8.   We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____   Date:___5/16/05_____
        Audrey Goddard

By: _____   Date:_____
        Paul J. Godowski

By: _____   Date:_____
        J. Christopher Grimaldi

By: _____   Date:_____
        Austin L. Gurney

By: _____   Date:_____
        William I. Wood

1764824
061205

agents, were also conceived prior to June 11, 1998, and included in the provisional application. Thus, conception of the invention claimed in the above-captioned patent application occurred prior to June 11, 1998.

6.   After these initial experiments, we continued to produce primers, clone and sequence other DNA sequences. We then began to identify the expression levels of the cloned sequences, and created constructs for expression of the encoded proteins. PCR primers for use in the detection of DNA58850 expression were designed on March 6, 2000 (see Exhibit A).

7.   Thereafter, the primers were used to test for expression of DNA58850 in various normal and tumor tissues. Exhibit B shows an experiment conducted in March 2000 testing for expression of DNA58850 in various normal tissues. Exhibit C shows an experiment performed on June 13, 2000, in which the primers were used to determine the expression level of DNA58850 in various tumor samples and their normal tissue counterparts. These gel data demonstrate that DNA58850 is more highly expressed in esophageal and kidney tumor than in normal esophageal and kidney tissue, respectively. These exhibits show diligence in reducing to practice following conception of the invention. Thus, we conceived of the present invention prior to June 11, 1998 and were diligent in reducing the invention to practice by at least June 13, 2000.

8.   We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____   Date:_____
        Audrey Goddard

By: _____   Date: 6/13/05
        Paul J. Godowski

By: _____   Date:_____
        J. Christopher Grimaldi

By: _____   Date:_____
        Austin L. Gurney

By: _____   Date:_____
        William I. Wood

1764824
061205

agents, were also conceived prior to June 11, 1998, and included in the provisional application. Thus, conception of the invention claimed in the above-captioned patent application occurred prior to June 11, 1998.

6.　　　After these initial experiments, we continued to produce primers, clone and sequence other DNA sequences. We then began to identify the expression levels of the cloned sequences, and created constructs for expression of the encoded proteins. PCR primers for use in the detection of DNA58850 expression were designed on March 6, 2000 (see Exhibit A).

7.　　　Thereafter, the primers were used to test for expression of DNA58850 in various normal and tumor tissues. Exhibit B shows an experiment conducted in March 2000 testing for expression of DNA58850 in various normal tissues. Exhibit C shows an experiment performed on June 13, 2000, in which the primers were used to determine the expression level of DNA58850 in various tumor samples and their normal tissue counterparts. These gel data demonstrate that DNA58850 is more highly expressed in esophageal and kidney tumor than in normal esophageal and kidney tissue, respectively. These exhibits show diligence in reducing to practice following conception of the invention. Thus, we conceived of the present invention prior to June 11, 1998 and were diligent in reducing the invention to practice by at least June 13, 2000.

8.　　　We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____　　　Date:_____
　　　　Audrey Goddard

By: _____　　　Date:_____
　　　　Paul J. Godowski

By: _____　　　Date:_____6/14/2005_____
　　　　J. Christopher Grimaldi

By: _____　　　Date:_____
　　　　Austin L. Gurney

By: _____　　　Date:_____
　　　　William I. Wood

1764824
061205

agents, were also conceived prior to June 11, 1998, and included in the provisional application. Thus, conception of the invention claimed in the above-captioned patent application occurred prior to June 11, 1998.

6.   After these initial experiments, we continued to produce primers, clone and sequence other DNA sequences. We then began to identify the expression levels of the cloned sequences, and created constructs for expression of the encoded proteins. PCR primers for use in the detection of DNA58850 expression were designed on March 6, 2000 (see Exhibit A).

7.   Thereafter, the primers were used to test for expression of DNA58850 in various normal and tumor tissues. Exhibit B shows an experiment conducted in March 2000 testing for expression of DNA58850 in various normal tissues. Exhibit C shows an experiment performed on June 13, 2000, in which the primers were used to determine the expression level of DNA58850 in various tumor samples and their normal tissue counterparts. These gel data demonstrate that DNA58850 is more highly expressed in esophageal and kidney tumor than in normal esophageal and kidney tissue, respectively. These exhibits show diligence in reducing to practice following conception of the invention. Thus, we conceived of the present invention prior to June 11, 1998 and were diligent in reducing the invention to practice by at least June 13, 2000.

8.   We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____   Date:_____
        Audrey Goddard

By: _____   Date:_____
        Paul J. Godowski

By: _____   Date:_____
        J. Christopher Grimaldi

By: _____   Date:_____6/17/03_____
        Austin L. Gurney

By: _____   Date:_____
        William I. Wood

1764824
061205

agents, were also conceived prior to June 11, 1998, and included in the provisional application. Thus, conception of the invention claimed in the above-captioned patent application occurred prior to June 11, 1998.

6.   After these initial experiments, we continued to produce primers, clone and sequence other DNA sequences. We then began to identify the expression levels of the cloned sequences, and created constructs for expression of the encoded proteins. PCR primers for use in the detection of DNA58850 expression were designed on March 6, 2000 (see Exhibit A).

7.   Thereafter, the primers were used to test for expression of DNA58850 in various normal and tumor tissues. Exhibit B shows an experiment conducted in March 2000 testing for expression of DNA58850 in various normal tissues. Exhibit C shows an experiment performed on June 13, 2000, in which the primers were used to determine the expression level of DNA58850 in various tumor samples and their normal tissue counterparts. These gel data demonstrate that DNA58850 is more highly expressed in esophageal and kidney tumor than in normal esophageal and kidney tissue, respectively. These exhibits show diligence in reducing to practice following conception of the invention. Thus, we conceived of the present invention prior to June 11, 1998 and were diligent in reducing the invention to practice by at least June 13, 2000.

8.   We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____   Date:_____
        Audrey Goddard

By: _____   Date:_____
        Paul J. Godowski

By: _____   Date:_____
        J. Christopher Grimaldi

By: _____   Date:_____
        Austin L. Gurney

By: _____   Date:___6|17|05_____
        William I. Wood

1764824
061205

User:grim

oli.out3_6_2000

Tue Aug 10 16:46:53 PDT 2004

xe12380 / XE12380

xe12380   User:grim Job: oli.out3_6_2000 Date: Tue Aug 10 16:46:53 PDT 2004
xe12380   User:grim Job: oli.out3_6_2000 Date: Tue Aug 10 16:46:53 PDT 2004
xe12380   User:grim Job: oli.out3_6_2000 Date: Tue Aug 10 16:46:53 PDT 2004
xe12380   User:grim Job: oli.out3_6_2000 Date: Tue Aug 10 16:46:53 PDT 2004

```
<16422.f10  OLI28176>AGTTGCAACTATGCTGGCAACTGGAGG
<16422.r10  OLI28177>CCCAGATGTTTCTTACTGGCTCCTCACTAATC
<16435.f10  OLI28178>GAGGCAACTAAAAAGGCTTCAAACGTTTTG
<16435.r10  OLI28179>CAAAATCAATAACGTCATCAGCTTCCTAACCATG
<23334.f10  OLI28180>CGTTGGTTGAAGGACCTAAATACCTGGC
<23334.r10  OLI28181>CTTCTATCATCACCCAGCTGCATGACC
<26843.f10  OLI28182>GCAAGTTCATGCTCTGAGTCCTGAAGAG
<26843.r10  OLI28183>GGTGCAGTGTCATAGAGGGTTAATCCATG
<26844.f10  OLI28184>CCAATTCTGAACATTCCCATCGTGC
<26844.r10  OLI28185>GTGCTGGGATTACAGGCGTGAGC
<26844.f10>CCAATTCTGAACATTCCCATCGTGC
<26844.r10>GTGCTGGGATTACAGGCGTGAGC
<30862.f10  OLI28186>CACCTGAAGGTGATGCTCCTGGAAG
<30862.r10  OLI28187>GCGGTTCCATCGCAGATGACC
<40621.f10  OLI28188>CTGGCTGCCCATCATGACCTCC
<40621.r10  OLI28189>CTCCTGCCTCAGCCTCCCGAGTAG
<44161.f10  OLI28190>GAAGGACATGCGCGTGCAGAC
<44161.r10  OLI28191>GAGCTGGTGCTTTCCGCTGCC
<44694.f10  OLI28192>CCACAGCTGATACGGCATCCTGC
<44694.r10  OLI28193>CCAGAGTCTGCATGAGCACCAATG
<48320.f10  OLI28194>CCTCACTAGCACCTGGAATGATGCTTTG
<48320.r10  OLI28195>CACTCATAAGTTGCACATATGCTCCAAGGTC
<48334.f10  OLI28196>CAAGGAGGCAAAATTTTGACAGGGAAGG
<48334.r10  OLI28197>CTACACACAGAATAAGGTTGGGGAATTAAGCTG
<48606.f10  OLI28198>CAGCATGCCAGGCCTCACG
<48606.r10  OLI28199>CTTTCTCAGGCCTCCTGGCCAATAG
<49141.f10  OLI28200>CCACGTATCTCATGTGCCGAATGTG
<49141.r10  OLI28201>GTGCAGCCTCACACTGCCTTCTCC
<49647.f10  OLI28202>GGCAGTGAACACATCTGATTTCCCACAG
<49647.r10  OLI28203>CCCTCAAAAGCCAGTTACATTACATGTTCACAG
<49819.f10  OLI28204>GGTTGCCATTCCATAGGTTTGGAGAGC
<49819.r10  OLI28205>GCATTCACCTACCTGTCTAACCCTCACATG
<49820.f10  OLI28206>GAGAAGCTGACTGAGGAAGGCTCTCCC
<49820.r10  OLI28207>CTACTGGAAGCAGGCACAGTGTCACTAGC
<53913.f10  OLI28208>GCTTCCGTCCCTGAATCCCTTCC
<53913.r10  OLI28209>GTGTGAAACTGCTTGGTGGCTGTTCC
<53978.f10  OLI28210>GTGATGAATGGTCACACACCGATGCAC
<53978.r10  OLI28211>GAATCCTGGGGGATCAAATCATATGAATG
<53996.f10  OLI28212>CCAGATGGCACGACACTGCCATG
<53996.r10  OLI28213>CCAGAACAGCAGTGAGGCAGATTGATG
<56050.f10  OLI28214>GAAGGCTTCCTGCAGGAGCAGTCTG
<56050.r10  OLI28215>CAGGCCAGGTGAGAGAGTACAAGTCTTGC
<56110.f10  OLI28216>GTAGCCGGCTTGGCTTTTGTAATTGG
<56110.r10  OLI28217>GGATGGCTGAGTTTCGCACATTGTG
<56410.f10  OLI28218>CCTGAAGCTAGTCCAGCTAGTACACCACAAATC
<56410.r10  OLI28219>CAATCCTCCTGACTTGTCTTCCCTAAGTGC
<56436.f10  OLI28220>GAAATGGATTAGCCAACCAGGGCAAC
<56436.r10  OLI28221>GGAGCAGGAACCAACTCAATGCACAG
<56855.f10  OLI28222>GCAACTTACAGCTGCACCGACAGTTG
<56855.r10  OLI28223>GAGAGCACTGGAATGATTTAGGGGTGG
<56859.f10  OLI28224>GGCTGTCTTAGTACTTCGCCTGACAGTTGTC
<56859.r10  OLI28225>CCATCAACTATGTGATCCCAAAGCGC
<56860.f10  OLI28226>CTTCATGTGGCAGCAAGTTTTCGAGC
<56860.r10  OLI28227>GAGACGCATGGGTGTAGCCTCAGG
<56865.f10  OLI28228>CTAACCAACTGGAAAAATGGATGAAACTCAATG
<56865.r10  OLI28229>GTCTGTCTGGGAAGCTGACTGCCAGAC
<56868.f10  OLI28230>GGATTCCGAGAATCATTGTCATGTACATGC
<56868.r10  OLI28231>GTTCCCTCCTCATTCCTTAATGAGTGCTTG
<56869.f10  OLI28232>CAACTTCGCCCTGGAGCAGCTCTTC
<56869.r10  OLI28233>CTCCAGCACCCTCAACATGATGTAGCC
```

```
<56870.f10  OLI28234>GAACTCGGAAGAGATGCTGTGGAATCC
<56870.r10  OLI28235>CCTGTCCCAGTAATGCCAACTTGGAG
<57699.f10  OLI28236>CCTACGGTGAGAAGCTTACCATAAGCTTGG
<57699.r10  OLI28237>CATGGCATGGCTACCGCTTCCTTAG
<57704.f10  OLI28238>GCCCCAATGCCAAGTACGTAATGAAG
<57704.r10  OLI28239>CAGTGTAAGCCAGCACACTGACCTCC
<57710.f10  OLI28240>CAGCCTCCAAGCCATCATCACCAAG
<57710.r10  OLI28241>GTCCTGAGCGACTGCCACCATG
<57711.f10  OLI28242>GCATCGAAGCCCGTGAAATCCAG
<57711.r10  OLI28243>GTCAGGCACTGTGGTGAAGGGAACG
<57827.f10  OLI28244>GCCATCAATGGACATGATCTTCGATATGG
<57827.r10  OLI28245>CCATGTTGTGGTTGGAGTCCAGGG
<57844.f10  OLI28246>CCGTGGAATGGAGTTGATCCCAACC
<57844.r10  OLI28247>GCCTATCTAAGGTCCCTTGCTGCAAGG
<58723.f10  OLI28248>GATAAAACATGCAGCCACAGGCTCTCC
<58723.r10  OLI28249>GGACCAGACTGTACTGTGGCCATGTACAC
<58737.f10  OLI28250>GCACACATTAAGAACCTGTTACAGCTCATTGTTG
<58737.r10  OLI28251>GAAGGCTATCAGCACCTGCAACCAGC
<58743.f10  OLI28252>CACATGCGTCACATGGCATTTC
<58743.r10  OLI28253>GTTCGCACCATTCTCCTGCCTCAG
<58846.f10  OLI28254>CCCAGCAGTGGGACAGCCAGAC
<58846.r10  OLI28255>CAAGACCTATGTTCTGGGGCAGCAGG
<58848.f10  OLI28256>GAACTCCCCACCTTTGCACGCTG
<58848.r10  OLI28257>GATGTGTCCTTCACTCACCCGCAGC
<58849.f10  OLI28258>CGAACACCTTGTACTGGGAGTTGAATCAG
<58849.r10  OLI28259>CATCACATAGCAGAGTTCCCTCAGCCCTG
<58850.f10  OLI28260>GCACCTGTCAAAGCCTAAAGTCACCATG
<58850.r10  OLI28261>CCACAGTGGAGTAAACCGTATTTGCTGG
<58853.f10  OLI28262>GGGACTGACCCTAGTCTGTGTCCATGC
<58853.r10  OLI28263>GGGATGCTGTATGGATAGGAAGGGATG
<58855.f10  OLI28264>CGAAGGATGGACATCCTGCAATGG
<58855.r10  OLI28265>GCTTAGAGACTCCACACAGACAGCCAAGG
<59211.f10  OLI28266>CAAGGTGACCTCGCAGGACACTGG
<59211.r10  OLI28267>CCTCCTGATCAGAAAGGGGCCTAACAG
<59213.f10  OLI28268>GAGGCTGACACCTTCATGTTTGGAGG
<59213.r10  OLI28269>CTCAGTGTGGTCTGGCAGGAACCG
<59497.f10  OLI28270>CCTGACCAAAAAATTCCCAGTAACCAGGC
<59497.r10  OLI28271>GTGGCCAAGTGGATAAAACAGTAGCAGTG
<59603.f10  OLI28272>CTGCTGTGGCTGCAGCTCTGC
<59603.r10  OLI28273>GACGCCAGGAAAACAGCCAGGTC
<59605.f10  OLI28274>GGAGTACCATCTTCCTCATGGGACCAG
<59605.r10  OLI28275>CATGGGAATTCAGTGGGACAACATCC
<59607.f10  OLI28276>CCACTACATGAGCATCACCATCTTGGTC
<59607.r10  OLI28277>CTGGCCAGTGACTGTCAGGTTCTCTG
<59609.f10  OLI28278>CATTCCACTTGTGTCACTGCTTGGAACC
<59609.r10  OLI28279>GGCATTGTTAAGCAAGGGCAGCAGAAG
<59610.f10  OLI28280>CTGCCTCTCAGCCCTTACCTGATGC
<59610.r10  OLI28281>CCCTGAGTTGCGAAGTGGCAGTC
<59612.f10  OLI28282>GTGAGCGGATGGACCTAGCACTTCC
<59612.r10  OLI28283>GACAGCTACTACTCGCCAGGTGTGCTG
<59613.f10  OLI28284>GAATGCAGCAACACCAGCGATGC
<59613.r10  OLI28285>GACCTGTGACTCCCACTTACTGGGCAG
<59616.f10  OLI28286>GTCAGGAGCCTGAAATCAGGCTGACTTC
<59616.r10  OLI28287>TCCTCCAGGCCAATCCTGACCC
<59619.f10  OLI28288>GTGCATGTTCCCTGTCTGGTGCC
<59619.r10  OLI28289>GAGTCCCTGAGGTTGGAGTCCTAGCATAGC
<59625.f10  OLI28290>GTATTCTGCCCTGCGCATCCCAC
<59625.r10  OLI28291>GACTCCTCCAGTGGCACTGCAGCTC
<59827.f10  OLI28292>CACTGCAGCTGCGCACAGTCG
<59827.r10  OLI28293>GGTGCTCTGAGAAGAGGTCAGAATGGC
```

3

```
<59828.f10  OLI28294>CTGCCGACACCGGACTTCAGC
<59828.r10  OLI28295>GCCAGCCGACCTTTCTGTGGTG
<59853.f10  OLI28296>CTCCTTAGCCCGTGTGAGCCTCAC
<59853.r10  OLI28297>GTGCAATCTCAGCTCACTGCAGCCTC
<59854.f10  OLI28298>GGAGAGGCCACCGGGACTTCAG
<59854.r10  OLI28299>GGGGCCTGCTGAAAGACAGGGTC
<60283.f10  OLI28300>CTGTTTCTGATGTGGGGTTCCTCCAC
<60283.r10  OLI28301>CCATTGGCTTTCAAGGACCTTTCCCAAC
<60619.f10  OLI28302>CAGGCCCAGTGGGTGGAATCTGTC
<60619.r10  OLI28303>CATCTCCCGAAGAGAGAAGTCCCAACC
<60625.f10  OLI28304>CCAGGAACCTGAGCTAGGTCAAAGACG
<60625.r10  OLI28305>GTGAATAGCCCCATCCTCTCTTGACCTC
<60629.f10  OLI28306>TGATCTGTCACCAAAGGAGGCCAACTC
<60629.r10  OLI28307>CAGGTATCAGTATGAAAAAGGATCTTTGTTCATCAC
<61755.f10  OLI28308>GAATGAGCCTATCAGCAGGGCTCTAGTTTC
<61755.r10  OLI28309>GGAAGCCAGAAGCCAGGAGGAGC
<64852.f10  OLI28310>CAAGCCCTGCAGACAGTCTGTCTCC
<64852.r10  OLI28311>GGCTGATGCTATCATATTGCTATGGACATTG
<66308.f10  OLI28312>CGACATCCAGGCCAAGGACCTG
<66308.r10  OLI28313>CATCCTTGGGATCTCATGGTTGGG
<68869.f10  OLI28314>GCGTACTCCACAGTGCAGAGAGTCGC
<68869.r10  OLI28315>GGCTATCCTAAGTACCTCATGAAGAGGAGGC
```

4